March 29, 2006 16:00 ET

Ceapro announces Corporate Officer appointments

EDMONTON, March 29 - Ceapro Inc. (TSX VENTURE:CZO) today announced the
appointment of two officers; Shawn McMillan is appointed Chief Financial
Officer and David Fielder is appointed Vice President Scientific Affairs.

Dr. Mark Redmond, Ceapro's President and CEO stated, "Ceapro is delighted
to announce the appointment of two such highly qualified and talented
individuals as officers of the corporation. The critical role that each of
these individuals plays in Ceapro today makes these appointments appropriate
and as we plan for Ceapro's future Shawn and David will play important roles
in corporate development and succession strategy"

Shawn McMillan, B.Comm., CA since joining Ceapro in 2005 in the position
of Corporate Secretary and Financial Controller, Shawn has been responsible
for financial planning and reporting, strategy support, productivity and
accounting processes, as well as compliance and risk management. Under his
guidance Ceapro has implemented policies in compliance with the highest North
American standards for public companies with respect to financial reporting,
audit, and corporate governance. Shawn is a native Albertan and graduate from
the University of Alberta.

David Fielder, M.Sc. joined Ceapro in 1996 and has played a major role in
the discovery, conception, and commercialization of all of Ceapro's core
technology. For the last five years, David has directed the Company's
operations at the Leduc manufacturing plant. He has also played an
increasingly significant role in technical marketing and customer recruitment
as Ceapro expands its markets. David is a graduate of the Carleton University
with a specialized degree in natural products chemistry.

About Ceapro Inc.

Ceapro Inc is a growth stage biotechnology company. Ceapro's core
technology is the extraction of functional, active ingredients from plants for
sale to the personal care and healthcare markets. We also manufacture our own
line of products for human and animal health, as well as providing screening
and diagnostic services using our proprietary CeaProve® technology. Ceapro
shares trade on the TSX Venture Exchange under the symbol CZO. To learn more
about Ceapro, log on to our website at www.ceapro.com. Shares Outstanding:
37,098,670, Recent Close: $0.27

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release.

This release may contain forward-looking statements. Various factors
could cause actual results to differ materially from those projected in
forward-looking statements. Although the Company believes that the forward-
looking statements contained herein are reasonable, it can give no assurance
that the Company's expectations are correct. All forward-looking statements
are expressly qualified in their entirety by this cautionary statement.

Contact Information

  • Dr. Mark Redmond, President and CEO, Ceapro
    Inc., Telephone: (780) 421-4555